Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 22, 2011Biomarkers

Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJiang WuZheJiang Academy of Agricultural SciencesPPPooja PungaliyaNanotherapeutics (United States)EKEugenia KraynovPfizer (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wu et al. (2011) studied this question.

synapsesocial.com/papers/6ab08aaed520de6832ebf4fahttps://doi.org/10.3109/1354750x.2011.643485
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Osteopontin-c Splicing Isoform Contributes to Ovarian Cancer Progression2011 · 96 citations
  2. 2Osteopontin: an emerging therapeutic target for anticancer therapy2006 · 50 citations
  3. 3Cell Type-specific Post-translational Modifications of Mouse Osteopontin Are Associated with Different Adhesive Properties2007 · 138 citations
  4. 4Control of osteopontin signaling and function by post‐translational phosphorylation and protein folding2007 · 282 citations